Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Unternehmen & Branche
| Name | Sagimet Biosciences Inc. |
|---|---|
| Ticker | SGMT |
| CIK | 0001400118 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 272,4 Mio. USD |
| Beta | 3,21 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -51,038,000 | -1.58 | 116,482,000 | 111,381,000 | |
| 2025-09-30 | 10-Q | -12,908,000 | -0.40 | 128,401,000 | 119,255,000 | |
| 2025-06-30 | 10-Q | -10,386,000 | -0.32 | 137,407,000 | 130,160,000 | |
| 2025-03-31 | 10-Q | -18,176,000 | -0.56 | 146,172,000 | 138,992,000 | |
| 2024-12-31 | 10-K | -45,567,000 | -1.45 | 160,259,000 | 155,805,000 | |
| 2024-09-30 | 10-Q | -14,619,000 | -0.45 | 174,775,000 | 170,683,000 | |
| 2024-06-30 | 10-Q | -8,118,000 | -0.25 | 189,020,000 | 183,292,000 | |
| 2024-03-31 | 10-Q | -6,629,000 | -0.23 | 194,528,000 | 190,018,000 | |
| 2023-12-31 | 10-K | 2,000,000 | -27,876,000 | -2.66 | 96,719,000 | 91,065,000 |
| 2023-09-30 | 10-Q | 2,000,000 | -6,353,000 | -0.35 | 102,925,000 | 97,875,000 |
| 2023-07-31 | 10-Q | 2,000,000 | ||||
| 2023-06-30 | 10-Q | -6,785,000 | -35.80 | 21,498,000 | -198,414,000 | |
| 2023-03-31 | 10-Q | -6,587,000 | -35.58 | -192,699,000 | ||
| 2022-12-31 | 10-K | -30,499,000 | -165.20 | 33,031,000 | -186,950,000 | |
| 2022-09-30 | 10-Q | -7,467,000 | -40.34 | -180,554,000 | ||
| 2022-06-30 | 10-Q | -7,102,000 | -38.37 | -173,420,000 | ||
| 2022-03-31 | 10-Q | -8,735,000 | -166,595,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-10 | Chauche Thierry | Officer, Chief Financial Officer | Open Market Sale | -1,312 | 5.36 | -7,032.71 | -100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.